Back to results
US 12,594,262 B2Granted
CAI nanoemulsions
AssigneeForwardVue Pharma, Inc.
InventorsAlan J. Franklin, Laurent Balenci, Srikanth Kakamanu, Robert Dempsey
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to nanoemulsions of 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide (carboxy-amido-triazole or CAI), methods of preparing thereof, and their use in the treatment of inflammatory optic neuropathies.
Claims16
A nanoemulsion formulation comprising 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide (CAI) and poly(D,L-lactic-co-glycolic acid) (PLGA), wherein the average particle size is less than 300 nm, and an ocular therapeutic substance selected from the group consisting of:
- a VEGF binding molecule and a tyrosine receptor kinase inhibitor.
Dependencies are inferred from the claim text.